Letter to the Editor: Capivasertib plus abiraterone in PTEN-deficient metastatic hormone sensitive prostate cancer: CAPItello-281 phase III study [0.03%]
读者来信：Capivasertib联合阿比特龙治疗PTEN缺陷型转移性雄激素敏感前列腺癌：CAPItello-281Ⅲ期研究
Fabio Turco,Ursula Maria Vogl,Hui Ming Lin et al.
Fabio Turco et al.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer: Updated Efficacy Results from the phase 3 EMBER-3 trial [0.03%]
Imlunestrant联合或不联合Abemaciclib治疗晚期乳腺癌：EMBER-3三期临床试验的疗效更新结果
K L Jhaveri,P Neven,M L Casalnuovo et al.
K L Jhaveri et al.
Background: At the primary progression-free (PFS) analysis, the phase 3 EMBER-3 trial in endocrine pretreated patients with ER+, HER2- advanced breast cancer (ABC) demonstrated significant PFS benefit with imlunestrant vs...
Deep Learning Discriminates Thymic Epithelial Tumors Histological Subtypes Using Digital Pathology [0.03%]
深度学习利用数字病理区分胸腺上皮肿瘤的组织学亚型
Matteo Sacco,Erica Pietroluongo,Anna Di Lello et al.
Matteo Sacco et al.
Background: Thymic epithelial tumors (TETs) are rare malignancies that pose significant diagnostic challenges due to their heterogeneous histological patterns and substantial interobserver variability in classification. D...
20th anniversary of adjuvant trastuzumab: reflections on a breakthrough moment [0.03%]
赫赛汀辅助治疗二十年：回望一个里程碑时刻
G Gentile,R Gerosa,E de Azambuja et al.
G Gentile et al.
Twenty years after its initial approval, trastuzumab remains a cornerstone in the treatment of patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC). Long-term follow-up from pivotal adjuvant tria...
The PARP inhibitor/Immunotherapy Paradox in Advanced Ovarian Cancer: Positive Endpoints, Perplexing Interpretations [0.03%]
晚期卵巢癌的PARP抑制剂/免疫治疗悖论：积极的研究结果，令人困惑的解释
Jonathan A Ledermann,Robert L Coleman
Jonathan A Ledermann
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer [0.03%]
德瓦鲁单抗联合卡铂/紫杉醇和贝伐单抗，以及奥拉帕利维持或安慰剂治疗BRCA野生型晚期卵巢癌患者的一项3期、随机试验
P Harter,F Trillsch,A Okamoto et al.
P Harter et al.
Background: Despite treatment advances in newly diagnosed advanced stage ovarian cancer (aOC), improved outcomes are needed. Patients and methods: ...
Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase 2 study from the Italian Sarcoma Group [0.03%]
TRA beadetidine-奥拉帕利联合用药或TRA beadetidine治疗蒽环类药物治疗失败后的晚期软组织肉瘤患者Ⅱ期TOMAS2研究（意大利肉瘤组）
L D&#x;Ambrosio,A Merlini,A Brunello et al.
L D&#x;Ambrosio et al.
Background: Advanced/metastatic soft tissue sarcomas (STS) remain an unmet clinical need. We previously reported the feasibility and preliminary activity of trabectedin-olaparib combination in patients with advanced STS p...
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial [0.03%]
特瑞普利单抗联合新辅助化疗治疗可切除非小细胞肺癌患者的随机III期RATIONALE-315研究：最终分析
C Wang,W Wang,H Liu et al.
C Wang et al.
Background: Peri-operative immunotherapy, particularly anti-programmed cell death protein-1 therapy, combined with neoadjuvant chemotherapy has emerged as one of the standard-of-care options for resectable non-small cell ...
Felix Blanc-Durand,Miriam Koopman,Sandip Pravin Patel et al.
Felix Blanc-Durand et al.
Standardizing Time-to-Event Reporting in Single-Arm BCG-Unresponsive Registration Trials: A Case for Kaplan-Meier [0.03%]
单臂卡介苗无反应登记试验中报告事件发生时间标准化的必要性：Kaplan-Meier方法的优势分析
S M Monda,J J Meeks,T Powles et al.
S M Monda et al.